Latest News

James Rickard is a Research Pharmacist and has been involved in translational research to deliver new therapeutic options to patients throughout his career.

Results of landmark gene editing study for ATTR Amyloidosis presented at the International Liver Congress 2022

RRI Lead Specialty Research Physician wins award for Cardiovascular risk factor analysis of data associated with UK grocery brand Tescos

We studied the cardiac safety of P218 using advanced QTc assessments and found doses of up to 1000mg do not prolong the QTc suggesting a low risk of drug induced arrhythmia.

Here we present the results of our recent work on the cardiac safety of cortexolone 17α-propionate (cortexolone).

12-lead resting ECGs are considered essential in clinical trials, but their limitations have led to increasing use of 12-lead Holter monitor devices.

Dr. Taubel explains to the New Scientist why patient safety is pivotal in phase I trials

Here we report our recent work on the cardiac safety of nolasiban.

Our results suggest that individuals who have previously been infected with SARS-CoV-2 achieve markedly higher antibody titres than those who have yet to show signs of infection.

Findings from our recent study show how cardiac ion channel blocking agents could increase the risk of sudden cardiac death in patients with type 1 diabetes, particularly in women.

We are delighted to extend the testing opportunity to support the wider community.

A positive antibody test should not lead people to forego well-established rules to curb the spread of the virus.